home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 28, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 461 active entries

FibroGen, Inc.

225 Gateway Blvd.
South San Francisco, CA 94080
United States of America, California
Toll free: 800-720-7203

Phone: 650-866-7200
Fax: 650-866-7201

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


FibroGen Inc., is a privately-held biotechnology company focused on the discovery, development, and commercialization of therpapeutics and biomaterials that address unmet needs in medical and pharmaceutical markets. FibroGen's therapeutic target areas include fibrosis, anemia, and ischemia. The Company develops and manufactures recombinant human collagens and gelatins.

Development Programs
FG-3019 is FibroGen's lead anti-fibrotic therapy currently in Phase I testing for the treatment of idiopathic pulmonary fibrosis (IPF). FG-3019 is a fully human monoclonal antibody designed to block the fibtotic effects of Connective Tissue Growth Factor (CTGF). The Company belives FG-3019 holds promise for treating patients with IPF and addresses a large, unmet medical need for the treatment of numerous fibroproliferative disorders including diabetic nephropathy, and potentially other forms of renal fibrosis and scleroderma. FibroGen has completed a human safety study of 8.5 kd recombinant gelatin, demonstrating the safety and suitability of this excipient as a stabilizing component in vaccine and biologic stabilization. A safety study of injectable synthetic human collagen for wrinkle correction is planned to commence in the first half of 2004. FibroGen is also developing a potential first-in-class small molecule treatment for anemia.

Fueling the Pipeline
FibroGen’s pipeline of novel therapeutics and recombinant collagens and gelatins is based on promising research programs that target multiple medical areas of large, unmet need. Our long-standing expertise in the areas of prolyl hydroxylases, growth factors, collagens, and other proteins involved in connective tissue biology has laid the foundation for these programs. FibroGen’s development candidates have been internally derived from three core discovery platforms centered on hypoxia-inducible factor (HIF), Connective Tissue Growth Factor (CTGF), and recombinant human collagens and gelatins. We take an integrated approach to drug discovery and development that relies on key FibroGen strengths in biology, chemistry, informatics, toxicology, pharmacology, product development, and medical and regulatory affairs.

Selected Categories:

Product Company   Service Company
- Research

Last update of this entry: April 06, 2004

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.